ThromboGenics Ltd.
1560 Broadway
10th Floor
Dublin
New York
10036
Tel: 212-201-0920
Fax: 212-201-0921
Website: http://www.thrombogenics.com/
About ThromboGenics Ltd.
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer. Our lead product, ocriplasmin (microplasmin), has completed two successful Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). ThromboGenics will commercialize this product via its own dedicated sales force in the United States and in Europe.In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer, in partnership with Roche.
ThromboGenics currently has around 80 employees at its headquarters in Leuven, Belgium, and at its facilities in Ireland and the United States. The Company is listed on Eurolist by Euronext Brussels under the symbol THR.
70 articles about ThromboGenics Ltd.
-
Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project
10/22/2018
Oxurion NV announced today it is extending its partnership with Retina Global
-
Oxurion NV Business Update – Q3 2018
10/19/2018
Shareholders’ Approval and Launch of Oxurion NV as new Company Name
-
ThromboGenics Ltd. Signs Global And Exclusive In-Licensing Agreement With Galapagos To Develop And Commercialize Integrin Antagonists For The Treatment Of Diabetic Eye Disease
3/17/2016
-
ThromboGenics Ltd. Enrolls First Patient In Phase II CIRCLE Trial Evaluating Multiple Doses Of Ocriplasmin To Induce A Total Posterior Vitreous Detachment In Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
1/13/2016
-
BioInvent Announces Plan To Initiate Clinical Development Of TB-403 In Pediatric Cancer Together With ThromboGenics Ltd.
3/17/2015
-
ThromboGenics Ltd.' JETREA® Available in Germany Public and Private Market
5/2/2013
-
ThromboGenics Ltd.' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, Now Launched in the UK
4/11/2013
-
ThromboGenics Ltd. Starts Trading as Part of the BEL20 Index Today
3/18/2013
-
ThromboGenics Ltd. Transparency Declaration
7/13/2012
-
ThromboGenics Ltd. Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin
6/7/2012
-
ThromboGenics Ltd. Announces That the FDA Intends to Grant Ocriplasmin Priority Review
2/2/2012
-
ThromboGenics Ltd. and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule
12/16/2011
-
ThromboGenics Ltd. and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule
12/16/2011
-
ThromboGenics Ltd. Hopes for Eye Treatment Launch in 2012
8/25/2011
-
ThromboGenics Ltd.'s Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
9/1/2010
-
BioInvent and ThromboGenics Ltd. to Receive EUR 10 Million Milestone as Partner Roche Begins New Clinical Study With TB-403
5/17/2010
-
ThromboGenics Ltd. and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumors
11/16/2009
-
BioInvent and ThromboGenics Ltd. Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)
10/29/2009
-
ThromboGenics Ltd. Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
10/5/2009
-
ThromboGenics Ltd. is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
9/11/2009